[Form 4] Beyond Air, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Beyond Air (XAIR) director reported an option repricing. On November 4, 2025, multiple stock option grants were repriced to an exercise price of $1.95 per share, effective the same day. The filing shows cancellations of prior options at higher strike prices (including $10.80 and $5.892) and corresponding grants at $1.95 for the same share amounts.

The company states that all other terms of the options remain unchanged. These awards were issued under the Amended and Restated 2013 Equity Incentive Plan and remain subject to the existing vesting schedules and the reporting person’s continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Forbes William P

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY NY 11530

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			400	(2)	(2)	Common Stock	400	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		400		(2)	(2)	Common Stock	400	(1)	400	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,250	(2)	(2)	Common Stock	1,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,250		(2)	(2)	Common Stock	1,250	(1)	1,250	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			1,500	(2)	(2)	Common Stock	1,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		1,500		(2)	(2)	Common Stock	1,500	(1)	1,500	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			2,000	(2)	(2)	Common Stock	2,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		2,000		(2)	(2)	Common Stock	2,000	(1)	2,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			2,250	(2)	(2)	Common Stock	2,250	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		2,250		(2)	(2)	Common Stock	2,250	(1)	2,250	D
Stock Options (Right to buy)	$5.892	11/04/2025		D(1)			3,750	(2)	(2)	Common Stock	3,750	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		3,750		(2)	(2)	Common Stock	3,750	(1)	3,750	D

Explanation of Responses:

1. On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

2. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ William P. Forbes	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beyond Air (XAIR) disclose in this Form 4?

A director reported an option repricing effective November 4, 2025, reducing exercise prices to $1.95 per share with other terms unchanged.

Which option prices were changed for XAIR?

Options previously priced at $10.80 and $5.892 were canceled and re-granted at $1.95 per share for the same share amounts.

Were specific grant sizes mentioned for XAIR options?

Yes. Examples include grants of 3,750 and 2,000 option shares, each repriced to $1.95 per share.

Do vesting terms change with the XAIR option repricing?

No. The company states all other terms remain unchanged; vesting follows the existing award agreements and continued service.

Under what plan were the XAIR options issued?

The options were issued under the Amended and Restated 2013 Equity Incentive Plan.

What is the effective date of the XAIR option repricing?

The repricing is effective on November 4, 2025.